CHAIRMAN MOSELEY: MR. KREY: The next presentation is a rebuttal by EML. At the request of the DAAG and the ORERP, EML has agreed to assist and participate in the quality assurance plan for Phase II. | _As Frosty indicated, DRI is indeed responsible for the conduct of the quality assurance plan, but we have been, and we will continue to be active iithe-design and logistics of that plan. The first viewgraph, subtasks if you will in thé-exper imental selection, the“in situ. (A). This identifies the various approach to Phase II. gamma spectrometry, soil These are the site sampling and sample 10 preparation, cestune137 analysis, and plutonium 239-240 analysis. I have il left off in that viewgraph one other task which will be coming down the 12 road much later. 13 and 240 nuclides. 14 the time comes, but it wil] bepart of this subtask. That is ;the mass isotopic analysis of the plutonium 239 That’sfar _down the road, and we'll address that when EML has been involved in “Bach of these tasks in one of three ways: 15 16 instruction, reference samples, and dupication. 17 has provided written instructions toeach: of the appropriate ORERP groups 18 for 19 concerned. 20 test its analytical) methods prior to proceeding with the actual Phase II 21 samples, 22 analyzed under previous EML programs. 23 ence samples and blank samples to DRI who will then—insert them blind into 24 the normal sample flow to the analytical contractor>—As faras duplication each of these subtasks, as far In reference samples: we have provided them as the As part of this plan, EML EML standard methods are at the présent time to allow REECo to with typical samples which have been In the future we will provide refer- 25 is concerned, EML has intercalibrated its in situ gamma spectrometry system 26 with the system from Livermore at a number of sites. 27 collected or retrieved soil samples from 13 sites where REECo had sampled 28 earlier. These particular samples 179 will be InOctober, we have processed and analyzed at